RhoVac AB
SEK0.000000
0
+SEK0.00+0%Monday 00:00
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Financials
-Profit Margin
Unprofitable0Revenue
-5.61MNet Income
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Chosa Oncology AB, together with its subsidiaries, engages in developing and commercializing medicines for the treatment of cancer in Sweden. It offers Platin-DRP, a multigene mRNA-based algorithm that predicts a patient's response to platinum-based chemotherapy; and LiPlaCis, a liposomal formulation of cisplatin, enabling delivery of chemotherapy agent directly to tumor sites. The company has a collaboration with Icahn School of Medicine to test biomarker guiding platin-immunotherapy in lung cancer. The company was formerly known as Chosa ApS. Chosa Oncology AB was incorporated in 2015 and is based in Malmö, Sweden.
Show More
CEO
Mr. Peter Buhl Jensen Adj Professor, M.D., Ph.D.
Employees
2
Country
Sweden
ISIN
SE0007784319
WKN
000A2P5V6
Listings
0 Comments
Share your thoughts
FAQs
What is RhoVac AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Stockholm Exchange exchange RhoVac AB stocks are traded under the ticker RHOVAC.ST.
What is RhoVac AB revenue for the last year?▼
RhoVac AB revenue for the last year amounts to 0 SEK.
What is RhoVac AB net income for the last year?▼
RHOVAC.ST net income for the last year is -5.61M SEK.
How many employees does RhoVac AB have?▼
As of November 2, 2026, the company has 2 employees.
In which sector is RhoVac AB located?▼
RhoVac AB operates in the Other sector.
When did RhoVac AB complete a stock split?▼
RhoVac AB has not had any recent stock splits.
Where is RhoVac AB headquartered?▼
RhoVac AB is headquartered in Malmö, Sweden.